It’s Time to Finally Kill the Zombies; Comment on “Universal Pharmacare in Canada”

author

  • Joel Lexchin School of Health Policy and Management, Faculty of Health, York University, Toronto, ON, Canada
Abstract:

The movement for a national pharmacare plan in Canada is growing, but at the same time the multinational pharmaceutical companies and their supporters are critical of such a move. The three major arguments that they make are that all that is needed is to “fill in the gaps,” ie, cover those who currently are uninsured or underinsured, that private drug plans are superior to public ones because they cover a larger number of drugs and that Canada cannot afford pharmacare. This commentary examines each of these arguments and makes the case that none of them is valid and that it is time to get on with implementing pharmacare.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability; Comment on “Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”

Canada’s federal government intends to take steps to implement national pharmacare so that all Canadians have prescription drug coverage they need at an affordable price. Relatively limited funds have so far been pledged to support national pharmacare, which raises the question: what kind of program is envisioned? Since the government has already introduced regulations intended to reduce new dr...

full text

Universal Pharmacare in Canada: A Prescription for Equity in Healthcare

Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Altho...

full text

It Won’t Be Easy: How to Make Universal Pharmacare Work in Canada

One of the glaring gaps in Canada’s universal healthcare system is the low level of public financing of prescription drugs - 42.7% of total spending in 2018. At the federal level there is renewed interest in moving towards universal coverage, supported by a recently commissioned report on how to achieve it. It will take superb political navigation to extract Canadian ph...

full text

Bioimpedance: Has Its Time Finally Come?

Bioimpedance, themeasurement of the frequency-dependent resistance to the flow of low energy electrical currents between two electrodes on or within the body, has been investigated for various medical applications for over 50 years. Applications in cardiology date back to at least 1966 and have included attempts to estimate stroke volume, cardiac output, cardiac contractility and lung fluid vol...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 9  issue 12

pages  528- 530

publication date 2020-12-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023